Excitement in the longevity space over peptides comes with the caveat that many claims about their life-extending potential are incomplete at best and unfounded at worst.
Interest around longevity research emerged across several talks on the opening day of the Financial Times’ 2026 Global Pharma and Biotech Summit held in London, UK, 10–11 November. During a dedicated panel on longevity therapeutics, experts agreed that though there are promising signs with peptides, data around their effects on lifespan are not yet conclusive, while in many cases claims of efficacy are largely unfounded.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Glucagon-like peptide-1 receptor agonists (GLP-1RA) have shown signs of age reversal by some metrics, according to Alex Zhavoronkov, CEO of Insilico Medicine. For example, proteomics data published in September 2026 by researchers from Novo and Harvard University found Novo’s GLP-1RA semaglutide reduced biological age by as much as four years in the heart, brain, lungs, and other organs. Semaglutide is marketed as Wegovy for treating obesity.
However, Zhavoronkov added that such data hasn’t been backed by conclusive mortality data showing an overall increased lifespan with GLP-1RAs. Such studies need to be large-scale and long-term to capture any benefit, which will take a long time to prove, he said.
Tim Spector, a professor of genetic epidemiology at King’s College London, UK, and a fixture in the online health space, said GLP-1RAs have been the biggest medical breakthrough he’s seen during his career. But the idea of these being miracle drugs for longevity is misguided, he added.
He in turn touted the potential of the gut microbiome as a predictor for future health. According to patient data tracked by ZOE, a health company Spector co-founded, GLP-1RA users often have poor gut health. A causative relationship has been suggested by some, but these drugs’ effects are still not fully understood.
In lieu of solid longevity data, unsubstantiated claims and misinformation have crept in. Zhavoronkov described “snake oil statements” being made about supposedly life-extending drugs like peptides. The issue is perpetuated by social media, according to Tina Vilsbøll, senior medical officer at Novo, who warned, “there is no quick fix in this area.”
The longevity space is also fraught with issues around trust. Greg Bailey, co-founder of Juvenescence, an aging-focused biotech, said companies developing longevity drugs will need to gain credibility and authenticity in the eyes of patients, particularly as a counter to the surprising uptake of untested peptides for longevity which he has seen.
Although, he noted that explaining clinical nuance to a mass audience could complicate attempts to gain trust. To counter this, Bailey’s company is employing celebrity advocates to reach patients.
